Brikeza (Syrup)

(Vitamin D3, calcium as calcium citrate, magnesium as magnesium sulphate dihydrate, zinc as zinc citrate trihydrate)

COMPOSITION

150 ml of syrup contains:

- vitamin D3 (cholecalciferol) 99 IU
- calcium (as calcium citrate) 150 mg
- magnesium (as magnesium sulphate dihydrate) 75 mg
- zinc (as zinc citrate trihydrate) 3 mg

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS

Brikeza is a combination drug that replenishes the deficiency of calcium, magnesium, zinc and vitamin D3, regulates phosphorus and calcium metabolism, enhances bone mineralization and osteotylus formation.

Vitamin D3 regulates calcium and phosphorus metabolism, bone structure building process; enhances intestinal absorption of calcium ions, protein synthesis in small intestine, liver and bones. It stimulates DNA synthesis in osteocytes, suppresses the function of osteoclasts and inhibits the processes of bone tissue involution.

Calcium is required for osteogenesis, normal mineralization of teeth, functioning of the blood coagulating system, processes of impulse conduction in nerve and muscle fibers, smooth heart functioning.

Magnesium is involved in calcium metabolism regulation, bone growth and mineralization; in combination with vitamin D, it contributes to bone homeostasis.

Zinc is a component of more than 80 enzymes in human body, required for formation of erythrocytes and other blood corpuscles. Zinc is involved in vision-related photochemical reactions, blood vessel gland activities.

PHARMACOKINETICS

Absorption of the drug components starts immediately after administration, about 1/3 of calcium is absorbed in gastrointestinal tract and distributes in the body; maximum amount of calcium is deposited in bone tissues. The main routes of excretion are in fecal masses and urine.
THERAPEUTIC INDICATIONS
- treatment and prevention of rachitis;
- prevention of osteoporosis (including osteoporosis in postmenopausal women, in elderly people);
- calcium metabolic imbalance (including calcium metabolic imbalance in pregnancy and lactation, recovery period);
- post-fracture rehabilitation;
- intensive growth period in childhood and adolescence;
- active sport activities;
- low calcium intake with food.

CONTRAINDICATIONS
- individual intolerance or hypersensitivity to the medicinal product ingredients;
- hypercalcaemia;
- D3 hypervitaminosis;
- hyperphosphataemia;
- hyperparathyroidism;
- severe renal insufficiency;
- children aged under 6 months.

ADVERSE EFFECTS
The medicinal product is usually well tolerated, but hypercalcaemia may be observed in long-term administration.

DOSAGE AND ADMINISTRATION
The medicinal product should be taken 15-20 minutes before food. Shake the syrup before use.

For children aged 6 months - 1 year – 2.5 ml 1-2 times a day.
For children aged 1-2 years - 5 ml 2 times a day.
For children aged 3-12 years - 10 ml 2 times a day.
For children above 12 years and adults - 10 ml 2-3 times a day.
For pregnant and lactating women - 10 ml 2-3 times a day.

A dose-measuring cup graduated on 2.5 ml, 3 ml, 5 ml, 7.5 ml, 10 ml, 15 ml is used for measuring
doses.

The treatment course and duration of treatment should be established by a physician.

PACKAGING

Syrup for oral administration in amber glass vial of 150 ml with screw protective cap equipped with a
safety ring.

1 vial together with a leaflet and measuring cup in a carton box.